Get all your news in one place.
100's of premium titles.
One app.
Start reading
AAP
AAP

CGBIO Signs Global Clinical and Exclusive Commercialization Agreement for NOVOSIS in the U.S., Canada and Australia

  • DePuy Synthes secures exclusive commercialization rights in North America and Australia; the two companies to jointly advance global clinical development and regulatory approvals, including FDA IDE and PMA pathways
  • Full-scale entry into North America, the world's largest bone graft substitute market; strategic partnership to expand in orthopaedics and bone regeneration sectors

SEOUL, South Korea, May 27, 2026 /PRNewswire/ -- CGBIO, a regenerative medicine company (CEO: Hyunseung Yu), announced that it has entered into a global clinical development and exclusive commercialization agreement with DePuy Synthes, a global orthopaedics solutions company, for the NOVOSIS bone graft substitute product portfolio in the United States, Canada, and Australia.

‘Novosis Putty’ Product image

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.